Cellectis gains first therapeutic licence to Japanese iPS cell technology
This article was originally published in Scrip
Executive Summary
The French genome engineering firm Cellectis has signed two non-exclusive agreements that give it access to patents deriving from the research on induced pluripotent stem (iPS) cells being conducted at the University of Kyoto in Japan.